8-K - VolitionRx Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

VolitionRx Limited announced full fiscal year 2025 financial results with 40% year-over-year revenue growth to $1.7 million and a 14% reduction in net loss, alongside recent financing activities.

Key Takeaways

1Full-year 2025 revenue was $1.7 million, representing 40% growth over the previous year.

2Operating expenses decreased by $4.8 million, or 17%, compared to the prior year.

3Net loss improved by 14% for the year versus 2024.

4Net cash used in operating activities was $19.7 million for the year, down 24%.

5Subsequent to year end, the Company raised approximately $7.3 million in net proceeds from equity and convertible notes.

6The Company received its first order for Nu.Q Cancer assays for clinical certification ahead of routine clinical use.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

. Results of Operations and Financial Condition.** The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instructio

Financial Results

9.01

. Financial Statements and Exhibits.** (d) Exhibits. | Exhibit Number | Description | |---|---| | 99.1 | Press Release of VolitionRx Limited, dated March 31, 20

Exhibits Only

Source Document

Results of Operations

Full Fiscal Year 2025

Metric	Value	Prior Period
Revenue	$1.70	$1.21
Operating Expenses	$23.53	$28.33
Net Loss	$0.00	$0.00

Transaction Details

Debt / Financing

Instrument: Convertible Note
Principal: 1.9
Use of Proceeds: General corporate purposes

Exhibits (2)

8-K

FORM 8-K

99.1

PRESS RELEASE